PLUR
PluriยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
PLUR Profile
Pluri Inc.
A developer of stem cell therapy products to treat multiple ischemic and inflammatory conditions
Biological Technology
05/11/2001
12/10/2007
NASDAQ Stock Exchange
127
06-30
Common stock
MATAM Advanced Technology Park, Building No. 5, Haifa, Israel 3508409
Engaged in the research, development, manufacturing, clinical trials and business development of cell therapy and related technologies.
Pluri Inc., a Nevada corporation, was registered on May 11, 2001. The biotechnology company relies on a proprietary cell amplification platform to develop scalable cell-based solutions covering the healthcare, food and agriculture sectors. Through a network of collaborative enterprises, the company promotes a diversified pipeline of products and services, covering categories such as cultivated food, regenerative medicine and cell-based raw materials. At the same time, the company has built a unique three-dimensional (" 3 D ") cell expansion technology platform, and has built an industrial-scale cell production facility that conforms to Good Manufacturing Practices (" GMP ") standards (currently using a self-declared compliance model). Its technology has been applied in the fields of regenerative medicine, immunotherapy, food technology, contract development and production organization (CDMO) and agricultural technology (AgTech). In the future, it plans to expand its technology to more industries and verticals that require large-scale and cost-effective cell augmentation solutions through cooperation, joint ventures, license agreements and other cooperation modes.
